short ragweed pollen allergen
Allergenapproved
Approved
Mar 13, 1924
Ambrosia artemisiifolia, with the common names common ragweed, annual ragweed, and low ragweed, is a species of the genus Ambrosia native to regions of the Americas. — Wikipedia
Clinical trial activity
30 trials · 32 clinical orgs · 4 marketing orgs
Phase 1
10
Phase 2
17
Phase 3
5
Phase 4
1
Earliest trial started Apr 1, 2003 (NCT00078195)
Timeline
1920s
- Mar 13, 1924
Jubilant Innovation Ltd. — Earliest FDA Approval
- Mar 13, 1924
Jubilant Innovation Ltd. — NDA Secondary Org
- Mar 13, 1924
Jubilant Innovation Ltd. — NDA Organization
1930s
- Jun 14, 1930
Greer Laboratories — NDA Secondary Org
- Jun 14, 1930
ALK-Abello, S.A. — NDA Secondary Org
1970s
- Mar 13, 1974
Allermed Laboratories — NDA Secondary Org
Indications
Approved for
Studied for
- Allergy and Immunology · Phase 2
- Arthritis, Rheumatoid · Phase 1
- Asthma · Phase 2
- Conjunctivitis · Phase 2/Phase 3
- Conjunctivitis, Allergic · Phase 1
- Hypersensitivity · Phase 4
- Hypersensitivity, Immediate · Phase 3
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1
- Rhinitis · Phase 2
- Rhinitis, Allergic · Phase 3
- Rhinitis, Allergic, Seasonal · Phase 3
Mechanism of action
- Grass allergenImmunity, desensitized
Grass allergen immunity, desensitized
Approval history
- approvedMar 13, 1924
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAmbrosia artemisiifolia ↗
- WikipediaAmbrosia_artemisiifolia ↗
Also known as
- ambrosia
- ambrosia
- ambrosia artemisiifolia allergen
- ambrosia artemisiifolia allergen extract
- pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia
- ragweed
- ragweed
- ragweed allergen
- ragwitek
- short ragweed pollen allergen extract
- short ragweed pollen allergenic extract
- slit one ragweed
- toleromune ragweed
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05346718 | N/A | Sep 30, 2022 | Fraunhofer, University of California, Irvine |
| NCT05119751 | Phase 4 | Oct 25, 2021 | ALK-Abello, S.A., Clinique Spécialisée en Allergies de la Capitale |
| NCT03758456 | Phase 1 | Nov 21, 2018 | HAL Allergy, Inflamax |
| NCT03038971 | Phase 1 | Mar 30, 2017 | Greer Laboratories, ORA, Inc. |
| NCT03496103 | Phase 1 | Feb 29, 2016 | University of Texas, Galveston |
| NCT02134262 | Phase 1/Phase 2 (Phase 2) | May 1, 2014 | Jichi Medical University, Takara Bio Inc. |
| NCT02061670 | Phase 2 | Jan 1, 2014 | Adiga Life Sciences, Inc., Circassia Limited |
| NCT02061709 | Phase 2 | Jan 1, 2014 | Adiga Life Sciences, Inc., Circassia Limited, Inflamax |
| NCT01925729 | N/A | Oct 1, 2013 | National Institute on Deafness and Other Communication Disorders (NIDCD), University of Pittsburgh |
| NCT01744353 | Phase 1 | Nov 1, 2012 | Brown University, Rhode Island Hospital |
| NCT01500642 | Phase 3 | Jun 1, 2011 | ALK-Abello, S.A., Luigi Sacco University Hospital |
| NCT01353079 | Phase 3 | Apr 1, 2011 | Greer Laboratories |
| NCT01361412 | Phase 2 | Mar 1, 2011 | Adiga Life Sciences, Inc., Circassia Limited, PRACS |
| NCT01198613 | Phase 2 | Sep 1, 2010 | Adiga Life Sciences, Inc., Circassia Limited, PRACS |
| NCT00770315 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2009 | ALK-Abello, S.A. |
| NCT00838565 | Phase 1 | May 1, 2009 | Pfizer |
| NCT00878774 | Phase 2 | Apr 1, 2009 | Adiga Life Sciences, Inc., Circassia Limited |
| NCT01224834 | Phase 1 | Jan 1, 2009 | IQVIA, Stallergenes |
| NCT00670384 | Phase 2 | Apr 29, 2008 | Antigen Laboratories, Inc. |
| NCT00599872 | Phase 3 | Mar 1, 2008 | Greer Laboratories |
Showing 20 of 30 trials
Page 1 / 2
Organizations
Research & Development (32)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergy Therapeutics | For profit | 6 | 6 | 3 | 2005 |
| Adiga Life Sciences, Inc. | For profit | 5 | 0 | 1 | 2009 |
| Circassia Limited | For profit | 5 | 5 | 1 | 2009 |
| ALK-Abello, S.A. | For profit | 4 | 2 | 3 | 2006 |
| Allied Research International | For profit | 3 | 0 | 2 | 2005 |
| Greer Laboratories | For profit | 3 | 3 | 2 | 2008 |
| Immune Tolerance Network | Academic/Hospital | 2 | 0 | 1 | 2003 |
| Inflamax | For profit | 2 | 0 | 2 | 2014 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2003 |
| PRACS | For profit | 2 | 0 | 1 | 2010 |
| Antigen Laboratories, Inc. | For profit | 1 | 1 | 1 | 2008 |
| Brown University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Clinique Spécialisée en Allergies de la Capitale | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Creighton University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Dynavax Technologies Corporation | For profit | 1 | 1 | 1 | 2007 |
| Fraunhofer | For profit | 1 | 1 | 1 | 2022 |
| HAL Allergy | For profit | 1 | 1 | 1 | 2018 |
| Healthcare Discoveries Inc. | For profit | 1 | 0 | 1 | 2006 |
| IQVIA | For profit | 1 | 0 | 1 | 2009 |
| Jichi Medical University | Academic/Hospital | 1 | 1 | 1 | 2014 |
32 organizations
Page 1 / 2
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ALK-Abello, S.A. | For profit | NDA2 | Jun 14, 1930 |
| Allermed Laboratories | For profit | NDA2 | Mar 13, 1974 |
| Greer Laboratories | For profit | NDA2 | Jun 14, 1930 |
| Jubilant Innovation Ltd. | For profit | NDA2 | Mar 13, 1924 |
| Jubilant Innovation Ltd. | For profit | NDA | Mar 13, 1924 |